sacituzumab govitecan (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Breast Cancer

Pending FDA approval for metastatic triple-negative breast cancer (mTNBC; [ie, ER-/PR-/HER2-]) in patients who previously received at least 2 prior therapies

Safety and efficacy not established

Next:

Pharmacology

Mechanism of Action

Sacituzumab govitecan is an antibody drug conjugate that contains SN-38, the active metabolite of irinotecan

Binds to topoisomerase I-DNA complex and prevents ligation of the cleaved DNA strand; this results in double-strand DNA breaks, and ultimately, cell death and termination of cellular replication

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.